Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Capital Cardiology Associates

Neither a doctor nor a teaching hospital

Research payments

$1,308,744

119 payments

Through program year 2025, Capital Cardiology Associates is reported as receiving $1,308,744 in research payments, across 119 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $291,766 16
2024 Research $188,698 11
2023 Research $208,412 25
2022 Research $479,776 28
2021 Research $21,161 13
2020 Research $35,992 6
2019 Research $82,939 20

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $919,071 20 payments
  2. Boston Scientific Corporation $148,235 45 payments
  3. CVRx, Inc. $78,695 15 payments
  4. Merck Sharp & Dohme Corporation $52,700 10 payments
  5. E.R. Squibb & Sons, L.L.C. $25,743 3 payments
  6. AstraZeneca Pharmaceuticals LP $24,480 8 payments
  7. Pfizer Inc. $22,048 13 payments
  8. Amgen Inc. $18,908 1 payment
  9. AstraZeneca UK Limited $18,866 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $299,221 6 payments
  2. Hps-4/Timi 65/Orion-4: A Double-Blind Randomized Placebo-Controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease $251,977 2 payments
  3. A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients $127,983 2 payments
  4. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $113,598 3 payments
  5. A Randomized, Controlled, Multicenter, Open-Label Trial Comparing A Post-Discharge Care Pathway Involving Aggressive LDL-C Management With Inclisiran With Usual Care in Patients With A Recent Acute Coronary Syndrome $108,486 1 payment
  6. Study name not reported $78,695 15 payments
  7. Lux Trends $64,454 19 payments
  8. HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease. $52,700 10 payments
  9. A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia $43,346 12 payments
  10. Lux DX Trends $40,151 13 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record